CG Oncology Inc. (CGON)
$63.13-1.08%Close
SELLCRISIS · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $5.6B
- Beta
- 0.24
- P/E (TTM)
- -23.57
- Short % float
- 15.86%
- Days to cover
- 8.5
- SI change
- -7.2%
- 1W
- -8.12%
- 1M
- -12.74%
- vs SPY 1W
- -8.54%
- vs SPY 1M
- -14.80%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 5
- VALUE
- 8
- GROWTH
- 4
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-15.1%
REV YoY-
ROE-25.2%
EPS YoY-
ROA-20.7%
GROSS-83
OP-4056
NET-3603
[VALUATION]
P/E TTM-23.57
P/E FWD-
SECTOR PE20.54
INDUSTRY PE14.03
P/B5.45
P/FCF-
EV/EBITDA-25.21
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.86
ALTMAN Z-
CURR RATIO22.22
ND/EBITDA-
BETA0.24
Company news
FAQ
- What is LOPJLB’s current signal on CGON?
- LOPJLB’s latest quantitative signal on CG Oncology Inc. (CGON) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CGON in?
- CG Oncology Inc. (CGON) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does CG Oncology Inc. (CGON) do?
- CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The companyâs product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 cl…